SeeThruEquity Initiates Coverage on BioCorRx Inc. with a Price Target of $0.13

NEW YORK, NY / ACCESSWIRE / July 22, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of BioCorRx Inc. (OTCQB: BICX) with a Price Target of $0.13.

The report is available here: BICX Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

With headquarters in Santa Ana, CA, BICX distributes and licenses the Start Fresh Program for alcoholism and opioid addiction to a growing network of clinics and addiction treatment centers across the country. BICX has begun to experience accelerating business trends of late, with the number of treatment centers that offer the Start Fresh Program(R) more than doubling over the last six quarters, which has also been a catalyst for rapid revenue growth. Indeed, since a rebranding of the company and a focus on growing by finding licensing and distribution partners, BICX has seen its top line rising quickly. Revenues grew by 111% YoY in 1Q15 after growing more than 60% from 2013 to 2014. We expect the company to continue these trends in 2015E, and view BICX as an intriguing, high risk / high reward enterprise in the specialized services subcategory of the health care industry.

“Given the multi-billion dollar market opportunity and even larger economic cost of treating alcohol and opioid substance abuse, as well as the lack of effective treatments in the current medical paradigm, we see a large opportunity for BICX as the company expands. With limited resources deployed to date, the company has more than doubled the number of clinics offering the Start Fresh Program in the last year while the number of patients undergoing the Start Fresh Program(R) treatment plan has risen by 402%. Considering the opportunity and apparent early traction garnered by the company, we see BICX as an intriguing, high risk / high reward enterprise in the specialized services subcategory of the health care industry.,” commented Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $0.13 per share.”

Additional highlights from the report are as follows:

Start Fresh Program achieving growing momentum

BICX has begun to experience accelerating business trends of late, with the number of licensed and contracted treatment centers offering the Start Fresh Program(R) more than doubling over the last six quarters, which has also been a catalyst for rapid revenue growth. Indeed, since a rebranding of the company and a focus on growing by finding licensing and distribution partners, BICX has seen its top line rising quickly with high margin revenue. Revenues grew by 111% YoY in 1Q15 after growing more than 60% from 2013 to 2014 – a year in which the company generated positive operating cash from operations. We expect BICX to continue its strong top line growth in 2015E as the company benefits from direct marketing efforts that spread awareness of the Start Fresh Program through campaigns in social media, TV, PR, and patient testimonials.

Alcoholism and opioid treatment a large and fragmented market

BICX’s Start Fresh Program(R) is a unique and proprietary approach to provide treatment for alcoholism and opioid addiction – two large and fragmented markets with ample room for growth and expansion. According to the Center for Diseases Control (CDC) there are over 38mn heavy drinkers in the United States. Indeed, the estimated market size for alcohol treatment is $22Bn per year, and the economic impact from heavy drinking is estimated at over $230Bn. Similarly, there are over 2mn Americans suffering from opioid addiction. There is a natural overlapping of end market applications for the Start Fresh Program(R), as opioids account for 18% alcohol treatment facility admissions.

Please review important disclosures on our website at www.seethruequity.com.

About BioCorRx, Inc.

BioCorRx, Inc.(R) (OTCQB: BICX) is an addiction treatment and rehabilitation company offering a unique approach to the treatment of substance abuse addiction. The Start Fresh Program(R), a medication-assisted treatment program, consists of two components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. Clinic reports show that the treatment program can be successful for individuals who complete the program.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 430766